This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AZRX AzurRx BioPharma (AZRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About AzurRx BioPharma Stock (NASDAQ:AZRX) Get AzurRx BioPharma alerts:Sign Up Key Stats Today's Range$2.05▼$2.2250-Day Range$2.40▼$41.0052-Week Range$3.36▼$26.30Volume126,966 shsAverage Volume628,703 shsMarket Capitalization$19.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL. Read More Receive AZRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZRX Stock News HeadlinesEntero Therapeutics Inc (ENTO)July 30, 2024 | investing.comHanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship ProgramApril 19, 2023 | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 23 at 1:00 AM | Weiss Ratings (Ad)First Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND FilingJanuary 15, 2023 | marketwatch.comFWBI First Wave BioPharma, Inc.September 16, 2022 | seekingalpha.comFirst Wave BioPharma Inc (FWBI)April 30, 2022 | investing.comFirst Wave BioPharma IncOctober 1, 2021 | reuters.comAzurRx BioPharma Changes Name to First Wave BioPharmaSeptember 21, 2021 | marketwatch.comSee More Headlines AZRX Stock Analysis - Frequently Asked Questions When did AzurRx BioPharma's stock split? AzurRx BioPharma shares reverse split before market open on Monday, September 13th 2021.The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did AzurRx BioPharma IPO? AzurRx BioPharma (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO. What other stocks do shareholders of AzurRx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AzurRx BioPharma investors own include SCYNEXIS (SCYX), NIO (NIO), Oncobiologics (OTLK), Bionano Genomics (BNGO), Marker Therapeutics (MRKR), Ocugen (OCGN) and 9 Meters Biopharma (NMTR). Company Calendar Today10/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:AZRX CIK1604191 Webwww.azurrx.com Phone(649) 699-7855FaxN/AEmployees12Year Founded2014Profitability EPS (Trailing Twelve Months)($11.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.67 million Net MarginsN/A Pretax MarginN/A Return on Equity-482.96% Return on Assets-258.47% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.76) per share Price / Book-2.74Miscellaneous Outstanding Shares9,326,000Free Float8,645,000Market Cap$19.40 million OptionableNot Optionable Beta1.51 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:AZRX) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AzurRx BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
